Effects of adrenal steroids on the bone metabolism of children with congenital adrenal hyperplasia

Annals of the New York Academy of Sciences

Volumn 1117, Issue , 2007, Pages 345-351

  Lin Su, Karen ^a   New, Maria I ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

21 hydroxylase deficiency; Adrenal steroids; Bone mineral density; CAH; Glucocorticoid; Osteoprotegerin; RANK L

Indexed keywords

ANDROGEN; CORTICOSTEROID; ESTROGEN; HYDROCORTISONE; MINERALOCORTICOID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADRENAL HYPERPLASIA; ANDROGEN BLOOD LEVEL; BONE DENSITY; BONE METABOLISM; CONFERENCE PAPER; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; SALT LOSING NEPHRITIS; STEROID 21 MONOOXYGENASE DEFICIENCY; STEROID THERAPY;

EID: 36549051650     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1402.040     Document Type: Conference Paper

References (40)

1. PANG, S.Y., M.A. WALLACE, L. HOFMAN, et al. 1988. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 81: 866-874.
2. SPEISER, P.W., B. DUPONT, P. RUBINSTEIN, et al. 1985. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am. J. Hum. Genet. 37: 650-667.
3. SHERMAN, S.L., C.E. ASTON, N.E. MORTON, et al. 1988. A segregation and linkage study of classical and nonclassical 21-hydroxylase deficiency. Am. J. Hum. Genet. 42: 830-838.
4. NEW, M., F. LORENZEN, A. LERNER, et al. 1983. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J. Clin. Endocrinol. Metab. 57: 320-326.
5. NEBERT, D.W., D.R. NELSON & M.J. COON. 1991. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 10: 1-14.
6. DUPONT, B., S.E. OBERFIELD, E.M. SMITHWICK, et al. 1977. Close genetic linkage between HLA and congenital adrenal hyperplasia (21-hydroxylase deficiency). Lancet 2: 1309-1312.
7. KRAWCZAK, M. & D.N. COOPER. 2003. The human gene mutation database. Trends Genet. 13: 121-122.
8. KERRIGAN, J.R., J.D. VELDHUIS, S.A. LEYO, et al. 1993. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J. Clin. Endocrinol. Metab. 76: 1505-1510.
9. ESTEBAN, N.V. & A.L. YERGEY. 1990. Cortisol production rates measured by liquid chromatography/mass spectrometry. Steroids 55: 152-158.
10. LINDER, B.L., N.V. ESTEBAN, A.L. YERGEY, et al. 1990. Cortisol production rate in childhood and adolescence. J. Pediatr. 117: 892-896.
11. ESTEBAN, N.V., T. LOUGHLIN, A.L. YERGEY, et al. 1991. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J. Clin. Endocrinol. Metab. 72: 39-45.
12. BRANDON, D.D., L.M. ISABELLE, M.H. SAMUELS, et al. 1999. Cortisol production rate measurement by stable isotope dilution using gas chromatography-negative ion chemical ionization mass spectrometry. Steroids 64: 372-378.
13. CANALIS, E. 1996. Clinical review 83: mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab. 81: 3441-3447.
14. CANALIS, E., J.P. BILEZIKIAN, A. ANGELI & A. GIUSTINA. 2004. Perspectives on glucocorticoid-induced osteoporosis. Bone 34: 593-598.
15. MANELLI, F. & A. GIUSTINA. 2000. Glucocorticoid-induced osteoporosis. Trends Endocrinol. Metab. 11: 79-85.
16. MAZZIOTTI, G., A. ANGELI, J.P. BILEZIKIAN, et al. 2006. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17: 144-149.
17. BRAATVEDT, G.D., M. JOYCE, M. EVANS, et al. 1999. Bone mineral density in patients with treated Addison's disease. Osteoporos. Int. 10: 435-440.
18. VALERO, M.A., M. LEON, M.P. RUIZ VALDEPENAS, et al. 1994. Bone density and turnover in Addison's disease: effect of glucocorticoid treatment. Bone Miner. 26: 9-17.
19. JODAR, E., M.P. VALDEPENAS, G. MARTINEZ, et al. 2003. Long-term follow-up of bone mineral density in Addison's disease. Clin. Endocrinol. (Oxf.) 58: 617-620.
20. HOFBAUER, L.C., F. GORI, B.L. RIGGS, et al. 1999. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140: 4382-4389.
21. MANELLI, F., R. CARPINTERI, S. BOSSONI, et al. 2002. Growth hormone in glucocorticoid-induced osteoporosis. Front Horm. Res. 30: 174-183.
22. ALLEN, D. 1996. Growth suppression by glucocorticoid therapy. Endocrinol. Metab. Clin. North Am. 25: 699-717.
23. CANALIS, E. 2005. Mechanisms of glucocorticoid action in bone. Curr. Osteoporos. Rep. 3: 98-102.
24. CAMERON, F.J., B. KAYMAKCI, E.A. BYRT, et al. 1995. Bone mineral density and body composition in congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 80: 2238-2243.
25. GUO, C.Y., A.P. WEETMAN & R. EASTELL. 1996. Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia. Clin. Endocrinol. (Oxf.) 45: 535-541.
26. MORA, S., F. SAGGION, G. RUSSO, et al. 1996. Bone density in young patients with congenital adrenal hyperplasia. Bone 18: 337-340.
27. GUSSINYE, M., A. CARRASCOSA, N. POTAU, et al. 1997. Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia. Pediatrics 100: 671-674.
28. PAGANINI, C., G. RADETTI, C. LIVIERI, et al. 2000. Height, bone mineral density and bone markers in congenital adrenal hyperplasia. Horm. Res. 54: 164-168.
29. DE ALMEIDA FREIRE, P.O., S.H. DE LEMOS-MARINI, A.T. MACIEL-GUERRA, et al. 2003. Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a cross-sectional study of factors involved in bone mineral density. J. Bone Miner. Metab. 21: 396-401.
30. FLEISCHMAN, A., J. RINGELHEIM, H.A. FELDMAN & C.M. GORDON. 2007. Bone mineral status in children with congenital adrenal hyperplasia. J. Pediatr. Endocrinol. Metab. 20: 227-235.
31. KING, J.A., A.B. WISNIEWSKI, B.J. BANKOWSKI, et al. 2006. Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 91: 865-869.
32. SHEVDE, N.K., A.C. BENDIXEN, K.M. DIENGER & J.W. PIKE. 2000. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. USA 97: 7829-7834.
33. CENCI, S., G. TORALDO, M.N. WEITZMANN, et al. 2003. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc. Natl. Acad. Sci. USA 100: 10405-10410.
34. ROGGIA, C., Y. GAO, S. CENCI, et al. 2001. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA 98: 13960-13965.
35. HOFBAUER, L.C., S. KHOSLA, C.R. DUNSTAN, et al. 1999. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140: 4367-4370.
36. GOHEL, A., M.B. MCCARTHY & G. GRONOWICZ. 1999. Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. Endocrinology 140: 5339-5347.
37. YEH, J.K., M.M. CHEN & J.F. ALOIA. 1996. Ovariectomy-induced high turnover in cortical bone is dependent on pituitary hormone in rats. Bone 18: 443-450.
38. YEH, J.K., M.M. CHEN & J.F. ALOIA. 1997. Effects of 17 beta-estradiol administration on cortical and cancellous bone of ovariectomized rats with and without hypophysectomy. Bone 20: 413-420.
39. DEVLETA, B., B. ADEM & S. SENADA. 2004. Hypergonadotropic amenorrhea and bone density: new approach to an old problem. J. Bone Miner. Metab. 22: 360-364.
40. KAWAI, H., M. FURUHASHI & N. SUGANUMA. 2004. Serum follicle-stimulating hormone level is a predictor of bone mineral density in patients with hormone replacement therapy. Arch. Gynecol. Obstet. 269: 192-195.